Johnson & Johnson (JNJ)
149.27
-0.65
(-0.43%)
USD |
NYSE |
May 03, 16:00
149.61
+0.34
(+0.23%)
After-Hours: 20:00
Johnson & Johnson Enterprise Value: 366.66B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 366.66B |
| May 02, 2024 | 368.22B |
| May 01, 2024 | 371.26B |
| April 30, 2024 | 355.40B |
| April 29, 2024 | 360.76B |
| April 26, 2024 | 359.13B |
| April 25, 2024 | 360.76B |
| April 24, 2024 | 364.88B |
| April 23, 2024 | 367.36B |
| April 22, 2024 | 366.30B |
| April 19, 2024 | 363.39B |
| April 18, 2024 | 358.17B |
| April 17, 2024 | 355.84B |
| April 16, 2024 | 355.07B |
| April 15, 2024 | 362.62B |
| April 12, 2024 | 362.45B |
| April 11, 2024 | 365.51B |
| April 10, 2024 | 368.90B |
| April 09, 2024 | 373.93B |
| April 08, 2024 | 372.25B |
| April 05, 2024 | 374.17B |
| April 04, 2024 | 374.44B |
| April 03, 2024 | 378.68B |
| April 02, 2024 | 387.03B |
| April 01, 2024 | 387.15B |
| Date | Value |
|---|---|
| March 31, 2024 | 388.13B |
| March 28, 2024 | 387.61B |
| March 27, 2024 | 387.05B |
| March 26, 2024 | 381.78B |
| March 25, 2024 | 380.45B |
| March 22, 2024 | 380.48B |
| March 21, 2024 | 381.73B |
| March 20, 2024 | 381.75B |
| March 19, 2024 | 382.84B |
| March 18, 2024 | 384.16B |
| March 15, 2024 | 387.58B |
| March 14, 2024 | 390.07B |
| March 13, 2024 | 394.62B |
| March 12, 2024 | 398.57B |
| March 11, 2024 | 394.93B |
| March 08, 2024 | 390.81B |
| March 07, 2024 | 389.25B |
| March 06, 2024 | 390.38B |
| March 05, 2024 | 391.90B |
| March 04, 2024 | 391.58B |
| March 01, 2024 | 397.08B |
| February 29, 2024 | 395.30B |
| February 28, 2024 | 395.71B |
| February 27, 2024 | 394.33B |
| February 26, 2024 | 393.71B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
301.41B
Minimum
Mar 23 2020
492.23B
Maximum
Apr 25 2022
417.38B
Average
421.83B
Median
Enterprise Value Benchmarks
| Amgen Inc | 221.30B |
| Eli Lilly and Co | 722.23B |
| Merck & Co Inc | 351.00B |
| Pfizer Inc | 215.90B |
| Shockwave Medical Inc | 12.10B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.255B |
| Revenue (Quarterly) | 21.38B |
| Total Expenses (Quarterly) | 15.11B |
| EPS Diluted (Quarterly) | 1.34 |
| Gross Profit Margin (Quarterly) | 69.55% |
| Profit Margin (Quarterly) | 15.22% |
| Earnings Yield | 10.17% |
| Operating Earnings Yield | 6.49% |
| Normalized Earnings Yield | 5.585 |